CA2932059C - Crystalline form i of ibrutinib - Google Patents

Crystalline form i of ibrutinib Download PDF

Info

Publication number
CA2932059C
CA2932059C CA2932059A CA2932059A CA2932059C CA 2932059 C CA2932059 C CA 2932059C CA 2932059 A CA2932059 A CA 2932059A CA 2932059 A CA2932059 A CA 2932059A CA 2932059 C CA2932059 C CA 2932059C
Authority
CA
Canada
Prior art keywords
crystalline form
ibrutinib
ray powder
powder diffraction
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2932059A
Other languages
English (en)
French (fr)
Other versions
CA2932059A1 (en
Inventor
Minhua Chen
Yanfeng Zhang
Chaohui YANG
Xiaoyu Zhang
Fei Lu
Heng GE
Peng Wang
Pixu Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Pharmatech Co Ltd
Suzhou Pengxu Pharmatech Co Ltd
Original Assignee
Crystal Pharmatech Co Ltd
Suzhou Pengxu Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmatech Co Ltd, Suzhou Pengxu Pharmatech Co Ltd filed Critical Crystal Pharmatech Co Ltd
Publication of CA2932059A1 publication Critical patent/CA2932059A1/en
Application granted granted Critical
Publication of CA2932059C publication Critical patent/CA2932059C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2932059A 2013-11-27 2014-11-26 Crystalline form i of ibrutinib Active CA2932059C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201310616065.4A CN103694241A (zh) 2013-11-27 2013-11-27 Pci-32765的新晶型a及其制备方法
CN201310616065.4 2013-11-27
CN201410542609.1A CN104327085B (zh) 2013-11-27 2014-10-14 Pci-32765的晶型a及其制备方法
CN201410542609.1 2014-10-14
PCT/US2014/067586 WO2015081180A1 (en) 2013-11-27 2014-11-26 Crystalline form i of ibrutinib

Publications (2)

Publication Number Publication Date
CA2932059A1 CA2932059A1 (en) 2015-06-04
CA2932059C true CA2932059C (en) 2019-07-02

Family

ID=50355928

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2932059A Active CA2932059C (en) 2013-11-27 2014-11-26 Crystalline form i of ibrutinib

Country Status (14)

Country Link
US (1) US9751889B2 (enExample)
EP (1) EP3073999B1 (enExample)
JP (1) JP6483126B2 (enExample)
CN (2) CN103694241A (enExample)
AU (1) AU2014354728B2 (enExample)
CA (1) CA2932059C (enExample)
DK (1) DK3073999T3 (enExample)
ES (1) ES2684094T3 (enExample)
HU (1) HUE039718T2 (enExample)
IL (1) IL245865B (enExample)
MX (1) MX363265B (enExample)
PL (1) PL3073999T3 (enExample)
PT (1) PT3073999T (enExample)
WO (1) WO2015081180A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37711A1 (fr) 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
EP3122753A4 (en) 2014-03-27 2017-11-29 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
CN105085529A (zh) * 2014-05-15 2015-11-25 广东东阳光药业有限公司 依鲁替尼新晶型及其制备方法
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
CA2958139A1 (en) 2014-08-14 2016-02-18 Assia Chemical Industries Ltd. Solid state forms of ibrutinib
CZ201584A3 (cs) 2015-02-09 2016-08-17 Zentiva, K.S. Sůl Ibrutinib sulfátu
US10477780B2 (en) * 2015-02-13 2019-11-19 Hgci, Inc. Multiple cell tray with media plugs
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
MX2017011990A (es) * 2015-03-20 2018-06-06 Crystal Pharmatech Co Ltd Metodo de preparacion de la forma a cristalina de pci-32765.
CN106153797B (zh) * 2015-04-20 2017-08-29 北京睿创康泰医药研究院有限公司 一种依鲁替尼及依鲁替尼制剂有关物质分析方法
CN106153798B (zh) * 2015-04-22 2017-08-29 北京睿创康泰医药研究院有限公司 一种用于分析依鲁替尼及依鲁替尼制剂有关物质的hplc方法以及这些杂质做参比标准的用途
EP3337485B1 (en) 2015-08-19 2021-03-17 Sun Pharmaceutical Industries Ltd Crystalline forms of ibrutinib
ITUB20155616A1 (it) * 2015-11-16 2017-05-16 Laboratorio Chimico Int S P A Procedimento per la preparazione della forma amorfa dell?ibrutinib e nuova forma cristallina.
CN105294696A (zh) * 2015-11-19 2016-02-03 上海创诺医药集团有限公司 依鲁替尼新晶型及其制备方法
CN106905320A (zh) * 2015-12-23 2017-06-30 杭州容立医药科技有限公司 一种适合药用的依鲁替尼及其制剂
CN106995445B (zh) * 2016-01-22 2021-08-03 山东新时代药业有限公司 一种布鲁顿酪氨酸激酶抑制剂晶型及其制备方法
CN107286163A (zh) * 2016-03-30 2017-10-24 上海星泰医药科技有限公司 一种依鲁替尼的新晶型及其制备方法
CZ2016196A3 (cs) 2016-04-06 2017-10-18 Zentiva, K.S. Pevné formy Ibrutinibu
CZ2016276A3 (cs) 2016-05-11 2017-11-22 Zentiva, K.S. Pevné formy volné báze ibrutinibu
CN106117214A (zh) * 2016-06-29 2016-11-16 上海创诺医药集团有限公司 依鲁替尼新晶型及其制备方法
CN106008529A (zh) * 2016-08-08 2016-10-12 上海工程技术大学 一种依鲁替尼溶剂化物及其制备方法
IL293319B1 (en) 2016-08-16 2026-01-01 Beone Medicines Ltd Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
WO2019070698A1 (en) 2017-10-02 2019-04-11 Johnson Matthey Public Limited Company Novel forms of ibrutinib
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
WO2019211870A1 (en) 2018-05-02 2019-11-07 Cipla Limited Polymorphic forms of ibrutinib
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
EP3810590A1 (en) * 2018-06-19 2021-04-28 Merck Patent GmbH Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
CN111138436A (zh) * 2018-11-04 2020-05-12 鲁南制药集团股份有限公司 伊布替尼晶型a单晶及其制备方法
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
EP3669867A1 (en) 2018-12-21 2020-06-24 Synthon B.V. Pharmaceutical composition comprising ibrutinib
CN113214261A (zh) * 2020-01-21 2021-08-06 尚科生物医药（上海）有限公司 一种依鲁替尼晶型a的纯化方法
TN2023000295A1 (en) 2021-06-10 2025-07-02 Hikma Pharmaceuticals Usa Inc Oral dosage forms of ibrutinib
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib
CN117752664A (zh) * 2023-12-13 2024-03-26 苏州晶云星空制药有限公司 一种包含伊布替尼晶型a的药物组合物及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007107469A1 (en) * 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Methods of inhibiting btk and syk protein kinases
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
PH12013500246A1 (en) 2010-08-10 2019-10-11 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
HK1206624A1 (en) 2012-04-11 2016-01-15 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
CN103142601A (zh) * 2013-03-13 2013-06-12 杭州雷索药业有限公司 Pci-32765在制备抗血管生成类药物中的应用

Also Published As

Publication number Publication date
WO2015081180A1 (en) 2015-06-04
EP3073999A1 (en) 2016-10-05
IL245865A0 (en) 2016-07-31
CN103694241A (zh) 2014-04-02
CN104327085B (zh) 2016-08-24
MX363265B (es) 2019-03-19
AU2014354728A1 (en) 2016-06-16
JP6483126B2 (ja) 2019-03-13
EP3073999B1 (en) 2018-05-30
PT3073999T (pt) 2018-10-16
MX2016006901A (es) 2016-10-28
JP2016538314A (ja) 2016-12-08
CA2932059A1 (en) 2015-06-04
CN104327085A (zh) 2015-02-04
HUE039718T2 (hu) 2019-02-28
EP3073999A4 (en) 2017-03-22
US9751889B2 (en) 2017-09-05
IL245865B (en) 2019-05-30
AU2014354728B2 (en) 2019-02-28
US20170002009A1 (en) 2017-01-05
ES2684094T3 (es) 2018-10-01
PL3073999T3 (pl) 2018-10-31
DK3073999T3 (en) 2018-09-03

Similar Documents

Publication Publication Date Title
US9751889B2 (en) Crystalline form I of ibrutinib
CN113993590B (zh) 新型egfr抑制剂
WO2022237815A1 (en) Novel forms of Compound I and use thereof
JP2026500533A (ja) Ｋｒａｓ ｇ１２ｄ阻害剤の結晶形及び調製方法
WO2020244348A1 (zh) 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型
US20250270221A1 (en) Solid forms of jak inhibitor and process of preparing the same
CN116554177B (zh) 一种含氮杂环化合物的盐型、晶型及其应用
CN115448874B (zh) 固体形式的周期蛋白依赖性激酶9抑制剂及其用途
CN114026088A (zh) Jak2抑制剂的结晶形式
US12428369B2 (en) Crystal form of aromatic vinyl derivatives, and preparation method therefor and use thereof
CA3224315A1 (en) Thiazole-lactam-spiroheterocyclic compounds and applications thereof
KR102967883B1 (ko) Fgfr4 억제제 산성염 및 이의 제조 방법과 응용
JP7762460B2 (ja) １Ｈ－ピロロ［２，３－ｃ］ピリジン系化合物の結晶形及びその製造方法
US20230265056A1 (en) Crystalline forms of benzamide compound and process for preparing the same
US20240368157A1 (en) Forms and compositions of a jak2 inhibitor
TW202545933A (zh) 一種吡唑基-胺基-嘧啶基衍生物的苯甲醯胺的晶型、製備方法及應用
WO2023041061A1 (zh) 一种稠合二环类衍生物的可药用盐、晶型及其制备方法
TW202346282A (zh) Shp2抑制劑之結晶鹽形式
HK40058904B (en) Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof
JP2012041331A (ja) ４−アミノ−５−クロロ−２−エトキシ−ｎ−［［４−（４−フルオロベンジル）−２−モルホリニル］メチル］ベンズアミド・クエン酸塩の結晶

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170913

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240904

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240904

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240904

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251014

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251015